Approaching Gold‐Standard Sensitivity in a Portable and Versatile Gold Nanoprisms Thermoplasmonic Platform for Lateral Flow Detection of Biomolecules

Why It Matters

By marrying laboratory‑grade sensitivity with field‑ready simplicity, this technology enables early disease detection and large‑scale screening outside conventional labs, accelerating clinical decision‑making.

Key Takeaways

• Gold nanoprisms convert NIR light to localized heat for signal amplification.
• ThermoLFIA outperforms ELISA in detecting CEA, CA19‑9, VEGF biomarkers.
• ThermoOLFA matches RT‑qPCR sensitivity for SARS‑CoV‑2 in 25 minutes.
• Platform requires no nucleic acid amplification, reducing assay complexity.
• Portable design supports point‑of‑care testing in resource‑limited settings.

Pulse Analysis

Plasmonic nanoparticles have reshaped diagnostic engineering, but gold nanoprisms (AuNPrs) stand out for their anisotropic shape and tunable near‑infrared resonance. Their high photothermal conversion efficiency turns them from passive labels into active nanotransducers, generating localized heat when illuminated. This property amplifies signal output far beyond conventional spherical gold tags, enabling visual readouts that approach laboratory‑grade sensitivity while retaining the simplicity of lateral flow formats.

The ThermoLFA platform exploits AuNPrs in two configurations: ThermoLFIA for protein biomarkers and ThermoOLFA for nucleic‑acid targets. In cancer screening, ThermoLFIA detected carcinoembryonic antigen, CA19‑9, and VEGF at concentrations lower than ELISA, suggesting earlier intervention possibilities for gastrointestinal malignancies. Simultaneously, ThermoOLFA identified SARS‑CoV‑2 RNA with a limit of detection rivaling RT‑qPCR, yet completed the assay in under half an hour without any amplification steps. This speed and sensitivity combination addresses the urgent need for rapid, accurate testing in pandemic response and routine clinical workflows.

From a market perspective, the blend of high sensitivity, low cost, and portable design positions ThermoLFA as a disruptive point‑of‑care solution. Healthcare providers in resource‑constrained settings can deploy the system for mass screening, while larger institutions may adopt it for rapid triage. Future development will likely focus on multiplexing capabilities, integration with smartphone readers, and regulatory pathways to accelerate commercialization. As the diagnostics landscape pivots toward decentralized testing, thermoplasmonic platforms like this could become a new gold standard for rapid, reliable biomarker detection.